Predicting anxiety and memory using brain and body signals
Developing the Context-Aware Multimodal Ecological Research and Assessment (CAMERA) Platform for Continuous Measurement and Prediction of Anxiety and Memory State
This study is testing a new system that uses different signals from the brain and body to see if it can better predict anxiety and memory issues in people with Temporal Lobe Epilepsy while they are in the hospital.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 40 (estimated) |
| Ages | 18 Years to 55 Years |
| Sex | All |
| Sponsor | Columbia University Academic / other |
| Locations | 1 site (New York, New York) |
| Trial ID | NCT06551090 on ClinicalTrials.gov |
What this trial studies
This study aims to develop the CAMERA platform, which utilizes multimodal sensor data to predict anxiety and memory states in patients with Temporal Lobe Epilepsy undergoing inpatient monitoring. By recording neural, physiological, behavioral, and environmental signals, CAMERA seeks to provide a continuous and high-resolution assessment of anxiety and cognitive performance. The platform incorporates context-aware assessments that adapt based on the patient's physiology and behavior, enhancing the accuracy of predictions. This innovative approach addresses the limitations of current behavioral measurement methods, allowing for a more comprehensive understanding of the relationships between brain activity, anxiety, and memory.
Who should consider this trial
Good fit: Ideal candidates for this study are patients with known or suspected Temporal Lobe Epilepsy who are proficient in English or Spanish.
Not a fit: Patients with current anxiety disorders, major depressive disorder, or bipolar disorder may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved methods for predicting and managing anxiety and cognitive performance in patients with epilepsy.
How similar studies have performed: While the approach is innovative, similar studies have shown promise in using multimodal data for behavioral predictions, indicating potential for success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients must have known or suspected Temporal Lobe Epilepsy. * Native or proficient in speaking English or Spanish. * Stereoelectroencephalography (sEEG) cases: The implant plan must include hippocampal head, body, and tail electrodes either unilaterally or bilaterally. * 7th grade reading level (minimum level considered literate for adults) Exclusion Criteria: * Hearing impaired (i.e., not corrected with a hearing aid) * Unable to read the newspaper at arm's length with corrective lenses. * Objective intellectual impairment (estimated IQ \< 70) * Any history of Electroconvulsive Therapy or psychosis (except postictal psychosis for patients) * Psychotic disorder (lifetime) * Current Anxiety disorder, Major Depressive Disorder, or Bipolar Disorder * Neurodegenerative diseases, presence of widespread brain lesions, language problems (other than naming difficulty) * Medical conditions that could potentially affect cognitive performance (e.g., human immunodeficiency virus (HIV) infection, cancer with metastatic potential). * Acute renal failure or end-stage renal disease
Where this trial is running
New York, New York
- Columbia University Irving Medical Center — New York, New York, United States (Recruiting)
Study contacts
- Principal investigator: Brett E Youngerman, MD — Columbia University
- Study coordinator: Brett E Youngerman, MD
- Email: bey2103@cumc.columbia.edu
- Phone: 516-946-2145
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.